Table 1.
Baseline characteristics and factors univariately differentiating between CHD and CHB based on ANOVA (continuous values) and Chi-square analysis (discrete values)
| Total cohort = 350 | CHD = 175 | CHB = 175 | p-value | |
|---|---|---|---|---|
| Sex (%) | Male = 240 (68.6%) | Male = 120 (68.6%) | Male = 120 (68.6%) | 0.55 |
| Female = 110 (31.4%) | Female = 55 (31.4%) | Female = 55 (31.4%) | ||
| Age, years, mean ± SD (range) | 37.6 ± 11.9 (15.0–67.9) | 38.5 ± 12.1 (16.0–67.9) | 36.8 ± 11.7 (15.0–64.4) | 0.17 |
| Country of origin (%) | Central Europe = 73 (20.9%) | Central Europe = 36 (20.6%) | Central Europe = 37 (21.1%) | 0.24 |
| Eastern Mediterranean = 123 (35.1%) | Eastern Mediterranean = 60 (34.3%) | Eastern Mediterranean = 63 (36.0%) | ||
| Eastern Europe = 128 (36.6%) | Eastern Europe = 64 (36.6%) | Eastern Europe = 64 (36.6%) | ||
| Other = 16 (4.6%) | Other = 6 (3.4%) | Other = 10 (5.7%) | ||
| AST, mean ± SD (range) | 91.2 ± 210.9 (30–2827) | 86.6 ± 91.6 (30–691) | 70.2 ± 166.5 (30–1390) | 0.04 |
| ALT, mean ± SD (range) | 122.1 ± 216.9 (31–2507) | 113.6 ± 143.9 (31–1238) | 67.1 ± 245.9 (32–2507) | 0.41 |
| AP, mean ± SD (range) | 113.9 ± 75.4 (9–616) | 117.5 ± 66.4 (9–512) | 105.1 ± 81.7 (25–616) | 0.13 |
| gGT, mean ± SD (range) | 75.1 ± 122.9 (5–1135) | 76.1 ± 84.1 (5–452) | 60.7 ± 123.8 (6–976) | 0.03 |
| Bilirubin, mean ± SD (range) | 18.9 ± 38.6 (5–478) | 16.5 ± 20.3 (5–148) | 18.3 ± 37.2 (5–348) | 0.32 |
| Albumin, mean ± SD (range) | 39.9 ± 6.9 (15–70) | 38.5 ± 5.9 (22–50) | 40.9 ± 7.4 (15–70) | < 0.01 |
| Platelets, mean ± SD (range) | 168.8 ± 80.4 (16–450) | 139.3 ± 74.7(16–377) | 194.8 ± 70.9 (23–398) | < 0.01 |
| INR, mean ± SD (range) | 1.15 ± 0.24 (1–3) | 1.21 ± 0.24 (1–3) | 1.10 ± 0.17 (1–2) | < 0.01 |
| MELD, mean ± SD (range) | 8.61 ± 3.03 (3.93 –25.4) | 9.52 ± 3.08 (5.4–21.1) | 8.10 ± 2.81 (5.24–25.4) | < 0.01 |
| Log HBV DNA mean ± SD (range) | 3.35 ± 2.41 (0–9.04) | 2.13 ± 1.89 (0–8.04) | 4.23 ± 2.36 (0–9.04) | < 0.01 |
| HBV DNA neg | 65 (18.5%) | 43 (28.1%) | 13 (8.7%) | < 0.01 |
| antiHBe pos | 239 (79.4%) | 121 (81.8%) | 118 (77.1%) | 0.32 |
| HBeAg positive, n (%) | 68 (19.4%) | 29 (15.7%) | 39 (22.3%) | 0.59 |
| Cirrhosis, n patients (%) | 110 (31.4%) | 79 (45.1%) | 31 (17.7%) | < 0.01 |
| Biopsy, n patients, fibrosis stage mean ± SD (range) | 174, 2.22 ± 1.81 (0–6) | 82, 3.45 ± 1.56 (0–6) | 92, 2.12 ± 1.77 (0–6) | < 0.01 |
| Fibroscan (kPa) mean ± SD (range) | 11.4 ± 10.17 (2.9–50.1) | 13.9 ± 11.12 (3.4–50.1) | 6.4 ± 5.24 (2.9–28.4) | < 0.01 |
| APRI, mean ± SD (range) | 2.12 ± 6.21 (0.1–33) | 3.32 ± 8.91 (0.2–33) | 1.18 ± 2.28 (0.1–20.9) | < 0.01 |
| FIB-4, mean ± SD (range) | 2.70 ± 3.51 (0.1–34.7) | 3.87 ± 4.36 (0.17–34.7) | 1.58 ± 1.82 (0.10–11.5) | < 0.01 |
| Antiviral therapy (%) | No therapy = 111 (31.7%) | No therapy = 44 (25.1%) | No therapy = 67 (38.3%) | < 0.01 |
| NA = 152 (43.4%) | NA = 64 (36.6%) | NA = 88 (50.3%) | ||
| IFN = 87 (24.9%) | IFN = 67 (38.3%) | IFN = 20 (11.4%) | ||
| Follow-up, mean ± SD (range) | 6.93 ± 5.12 (0.60–23.6) | 6.29 ± 4.97 (0.60–23.6) | 7.57 ± 5.22 (0.60–22.9) | 0.02 |